{"id":37994,"date":"2025-07-28T11:58:10","date_gmt":"2025-07-28T03:58:10","guid":{"rendered":"https:\/\/flcube.com\/?p=37994"},"modified":"2025-07-28T11:58:10","modified_gmt":"2025-07-28T03:58:10","slug":"velavigo-closes-60-million-pre-a-financing-round-to-advance-global-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37994","title":{"rendered":"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials"},"content":{"rendered":"\n

Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing round. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital. Existing investors, including HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital, also increased their commitments. This funding will accelerate the advancement of Velavigo’s core programs into global clinical trials and bolster the development of its first-in-class (FIC) and best-in-class (BIC) drug candidates.<\/p>\n\n\n\n

Company Overview<\/strong>
Velavigo is a leading biotech company specialized in antibody and antibody-drug conjugate (ADC) discovery and development. The company boasts a highly efficient discovery engine and robust capabilities in translational medicine, CMC, and early clinical development.<\/p>\n\n\n\n

Business Model and Pipeline<\/strong>
Velavigo employs a dual-engine model combining in-house innovation with global partnerships. This strategy has enabled the company to build a globally competitive pipeline, with over ten programs reaching the preclinical candidate (PCC) stage. The lead oncology program is on track to enter clinical trials in both China and the U.S. in 2025.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing…<\/p>\n","protected":false},"author":1,"featured_media":37995,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,2191],"class_list":["post-37994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-velavigo"],"yoast_head":"\nVelavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing round. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital. Existing investors, including HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital, also increased their commitments. This funding will accelerate the advancement of Velavigo's core programs into global clinical trials and bolster the development of its first-in-class (FIC) and best-in-class (BIC) drug candidates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37994\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing round. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital. Existing investors, including HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital, also increased their commitments. This funding will accelerate the advancement of Velavigo's core programs into global clinical trials and bolster the development of its first-in-class (FIC) and best-in-class (BIC) drug candidates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37994\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-28T03:58:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials\",\"datePublished\":\"2025-07-28T03:58:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2802.webp\",\"keywords\":[\"Finance\",\"VelaVigo\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37994#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37994\",\"name\":\"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2802.webp\",\"datePublished\":\"2025-07-28T03:58:10+00:00\",\"description\":\"Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing round. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital. Existing investors, including HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital, also increased their commitments. This funding will accelerate the advancement of Velavigo's core programs into global clinical trials and bolster the development of its first-in-class (FIC) and best-in-class (BIC) drug candidates.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37994\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37994#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials - Insight, China's Pharmaceutical Industry","description":"Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing round. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital. Existing investors, including HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital, also increased their commitments. This funding will accelerate the advancement of Velavigo's core programs into global clinical trials and bolster the development of its first-in-class (FIC) and best-in-class (BIC) drug candidates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37994","og_locale":"en_US","og_type":"article","og_title":"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials","og_description":"Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing round. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital. Existing investors, including HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital, also increased their commitments. This funding will accelerate the advancement of Velavigo's core programs into global clinical trials and bolster the development of its first-in-class (FIC) and best-in-class (BIC) drug candidates.","og_url":"https:\/\/flcube.com\/?p=37994","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-28T03:58:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37994#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37994"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials","datePublished":"2025-07-28T03:58:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37994"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2802.webp","keywords":["Finance","VelaVigo"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37994#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37994","url":"https:\/\/flcube.com\/?p=37994","name":"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37994#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2802.webp","datePublished":"2025-07-28T03:58:10+00:00","description":"Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing round. The round was led by Shunwei Capital, with participation from Northern Light Venture Capital (NLVC), Han Kang Capital, Everest VC, Songqing Capital, and Lingang Lanwan Capital. Existing investors, including HighLight Capital (HLC), Shanghai Healthcare Capital (SHC), Delian Capital, Legend Star, and Zoo Capital, also increased their commitments. This funding will accelerate the advancement of Velavigo's core programs into global clinical trials and bolster the development of its first-in-class (FIC) and best-in-class (BIC) drug candidates.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37994#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37994"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37994#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2802.webp","width":1080,"height":608,"caption":"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37994#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37994"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37994\/revisions"}],"predecessor-version":[{"id":37996,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37994\/revisions\/37996"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37995"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}